WILEX reports on Annual General Meeting 2012


• Dr Birgit Kudlek elected as new member of the Supervisory Board
FDA confirms Advisory Committee meeting

PDF Download back

Munich, Germany, 25 May 2012. WILEX AG (ISIN DE0006614720 / WL6 / FWB) today announced that the Company’s ordinary Annual General Meeting has elected Dr Birgit Kudlek as a new member of the Supervisory Board. Dr Kudlek succeeds Dr Alexandra Goll, who stepped down from the Supervisory Board effective December 2011.

“We are pleased to have Dr Kudlek as a further member of the Supervisory Board with excellent industry knowledge and experience in the development and manufacturing of pharmaceutical products” commented Professor Christof Hettich, Chairman of WILEX AG’s Supervisory Board.

The shareholders of WILEX AG approved all management proposals put to vote at the meeting with a large majority including:

At the Annual General Meeting of WILEX AG 73.34% of the voting shares were represented.

At the meeting WILEX presented the current status of the clinical trials. The Company had previously informed its shareholders that the FDA proposed using an Advisory Committee to review the development strategy for REDECTANE®. The FDA has now confirmed that the Oncologic Drugs Advisory Committee (ODAC), scheduled for the 25th July 2012, will be the forum for this discussion. The ODAC will be asked to discuss and provide general advice on the extent to which, if any, the pre-surgical identification of clear cell carcinoma of the kidney using an imaging test provides useful clinical information.

All information regarding the Annual General Meeting is published on the Company’s website: http://www.wilex.de/press-investors/annual-general-meeting/agm2012/

Katja Arnold (CIRO)
Grillparzerstrasse 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors [at] wilex.com

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company has a broad portfolio of diagnostic and therapeutic products for the specific detection and targeted treatment of various types of cancer. WILEX’s therapeutic product candidates are based on antibodies (RENCAREX® in Phase III) and small molecules (MESUPRON® in Phase II, WX-554 in Phase Ib/II and WX-037 in preclinical development). In the field of diagnostics, REDECTANE® is an antibody-based, imaging in vivo diagnostic agent that is currently in a Phase III programme. WILEX’s US subsidiary WILEX Inc. in Cambridge, MA, markets a portfolio of research use only tests and in vitro diagnostic agents under the brand Oncogene Science, which are used as companion diagnostics for clinical trials and therapy monitoring. The wholly owned subsidiary Heidelberg Pharma GmbH offers an attractive and highly promising antibody drug conjugate technology platform and preclinical contract research services. The business model of WILEX comprises research, technology, product development and commercialisation. WILEX’s customers and partners include leading international pharmaceutical companies.
Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Seite gelesen: 437 | Heute: 2